The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
Open accessAbstract
SUMMARY Immune checkpoint blockade therapies fail to induce responses in majority of cancer patients; so how to increase the objective response rate becomes an urgent challenge. Here we demonstrate that sufficient T cell infiltration in tumor tissues is a prerequisite for response to PD-L1 blockade. Targeting tumors with tumor necrosis factor superfamily member LIGHT activates lymphotoxin beta receptor signaling, leading to the production of chemokines that recruit massive numbers of T cells. Furthermore, targeting non-T cell-inflamed tumor tissues by antibody-guided LIGHT creates a T cell-inflamed microenvironment and overcomes tumor resistance to checkpoint blockade. Our data indicates that targeting LIGHT might be a potent strategy to increase the responses to checkpoint blockades and other immunotherapies in non-T cell-inflamed tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“Recent clinical trials with anti-PD-1 and PD-L1 monoclonal antibodies have shown unprecedented durable responses in some patients with a variety of cancers (Brahmer et al., 2012; Topalian et al., 2012).”
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Self-citationIwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Yeast surface display for screening combinatorial polypeptide libraries
Boder, E. T., & Wittrup, K. D. (1997) · Nature Biotechnology · doi:10.1038/nbt0697-553 · Cited by 1,760
Tumor-Infiltrating CD8+Lymphocytes Predict Clinical Outcome in Breast Cancer
Mahmoud, S. M. A., Paish, E. C., Powe, D. G., Macmillan, R. D., Grainge, M. J., Lee, A. H. S., Ellis, I. O., & Green, A. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5037 · Cited by 1,367
Lee, Y., Auh, S. L., Wang, Y., Burnette, B., Wang, Y., Meng, Y., Beckett, M., Sharma, R., Chin, R., Tu, T., et al. (2009) · Blood · doi:10.1182/blood-2009-02-206870 · Cited by 1,324
Self-citationBlockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. (2015) · Nature · doi:10.1038/nature15520 · Cited by 1,201
Chemokines and Cell Migration in Secondary Lymphoid Organs
Cyster, J. G. (1999) · Science · doi:10.1126/science.286.5447.2098 · Cited by 1,031
The Lymphotoxin-β Receptor Induces Different Patterns of Gene Expression via Two NF-κB Pathways
Dejardin, E., Droin, N. M., Delhase, M., Haas, E., Cao, Y., Makris, C., Li, Z.-W., Karin, M., Ware, C. F., & Green, D. R. (2002) · Immunity · doi:10.1016/s1074-7613(02)00423-5 · Cited by 922
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
Melero, I., Shuford, W. W., Newby, S. A., Aruffo, A., Ledbetter, J. A., Hellström, K. E., Mittler, R. S., & Chen, L. (1997) · Nature Medicine · doi:10.1038/nm0697-682 · Cited by 898
‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization
Ridgway, J. B. B., Presta, L. G., & Carter, P. (1996) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/9.7.617 · Cited by 810
Blank, C., Brown, I., Peterson, A. C., Spiotto, M., Iwai, Y., Honjo, T., & Gajewski, T. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3259 · Cited by 772
T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
Crespo, J., Sun, H., Welling, T. H., Tian, Z., & Zou, W. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.12.003 · Cited by 752
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis
Hwang, W.-T., Adams, S. F., Tahirovic, E., Hagemann, I. S., & Coukos, G. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.09.039 · Cited by 661
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
Wilmott, J. S., Long, G. V., Howle, J. R., Haydu, L. E., Sharma, R. N., Thompson, J. F., Kefford, R. F., Hersey, P., & Scolyer, R. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2479 · Cited by 652
DEVELOPMENT AND MATURATION OF SECONDARY LYMPHOID TISSUES
Fu, Y.-X., & Chaplin, D. D. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.399 · Cited by 616
Self-citationOrchestrating the orchestrators: chemokines in control of T cell traffic
Bromley, S. K., Mempel, T. R., & Luster, A. D. (2008) · Nature Immunology · doi:10.1038/ni.f.213 · Cited by 593
Innate Immune Recognition of Cancer
Woo, S.-R., Corrales, L., & Gajewski, T. F. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112043 · Cited by 571
Spranger, S., Koblish, H. K., Horton, B., Scherle, P. A., Newton, R., & Gajewski, T. F. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-3 · Cited by 552
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer—Response
Sznol, M., & Chen, L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2234 · Cited by 528
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer
Sznol, M., & Chen, L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2063 · Cited by 488
Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity.
Chen, L., McGowan, P., Ashe, S., Johnston, J., Li, Y., Hellström, I., & Hellström, K. E. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.2.523 · Cited by 462
NETWORK COMMUNICATIONS: Lymphotoxins, LIGHT, and TNF
Ware, C. F. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115719 · Cited by 441
Yu, P., Lee, Y., Liu, W., Krausz, T., Chong, A., Schreiber, H., & Fu, Y.-X. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041684 · Cited by 432
Self-citationImproved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients
Cha, E., Klinger, M., Hou, Y., Cummings, C., Ribas, A., Faham, M., & Fong, L. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008211 · Cited by 383
Priming of naive T cells inside tumors leads to eradication of established tumors
Yu, P., Lee, Y., Liu, W., Chin, R. K., Wang, J., Wang, Y., Schietinger, A., Philip, M., Schreiber, H., & Fu, Y.-X. (2004) · Nature Immunology · doi:10.1038/ni1029 · Cited by 356
Self-citationThe evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
Shin, D. S., & Ribas, A. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.006 · Cited by 346
Barreira da Silva, R., Laird, M. E., Yatim, N., Fiette, L., Ingersoll, M. A., & Albert, M. L. (2015) · Nature Immunology · doi:10.1038/ni.3201 · Cited by 337
Monocyte/macrophage infiltration in tumors: modulators of angiogenesis
Dirkx, A. E. M., oude Egbrink, M. G. A., Wagstaff, J., & Griffioen, A. W. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.0905495 · Cited by 326
Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses
Yang, X., Zhang, X., Fu, M. L., Weichselbaum, R. R., Gajewski, T. F., Guo, Y., & Fu, Y.-X. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.004 · Cited by 269
Self-citationTumor masses support naive T cell infiltration, activation, and differentiation into effectors
Thompson, E. D., Enriquez, H. L., Fu, Y.-X., & Engelhard, V. H. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092454 · Cited by 249
Self-citationBoussemart, L., Routier, E., Mateus, C., Opletalova, K., Sebille, G., Kamsu-Kom, N., Thomas, M., Vagner, S., Favre, M., Tomasic, G., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt015 · Cited by 207
Wick, M., Dubey, P., Koeppen, H., Siegel, C. T., Fields, P. E., Chen, L., Bluestone, J. A., & Schreiber, H. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.2.229 · Cited by 195
Lymphoid neoorganogenesis: Lymphotoxin’s role in inflammation and development
Ruddle, N. H. (1999) · Immunologic Research · doi:10.1007/bf02786481 · Cited by 179
Lee, Y., Chin, R. K., Christiansen, P., Sun, Y., Tumanov, A. V., Wang, J., Chervonsky, A. V., & Fu, Y.-X. (2006) · Immunity · doi:10.1016/j.immuni.2006.06.016 · Cited by 174
Self-citationHVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation
del Rio, M., Lucas, C. L., Bühler, L. H., Rayat, G. R., & Rodríguez-Barbosa, J.-I. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0809590 · Cited by 161
Signaling via LTβR on the lamina propria stromal cells of the gut is required for IgA production
Kang, H.-S., Chin, R., Wang, Y., Yu, P., Wang, J., Newell, K. A., & Fu, Y. (2002) · Nature Immunology · doi:10.1038/ni795 · Cited by 149
Self-citationPhase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).
Hammers, H. J., Plimack, E. R., Infante, J. R., Ernstoff, M. S., Rini, B. I., McDermott, D. F., Razak, A. R. A., Pal, S. K., Voss, M. H., Sharma, P., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.4504 · Cited by 141
Targeting the Lymphotoxin-β Receptor with Agonist Antibodies as a Potential Cancer Therapy
Lukashev, M., LePage, D., Wilson, C. A., Bailly, V., Garber, E. A., Lukashin, A., Ngam-ek, A., Zeng, W., Allaire, N., Perrin, S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0217 · Cited by 125
Oncolytic Adenoviruses for the Treatment of Human Cancer: Focus on Translational and Clinical Data
Pesonen, S. A., Kangasniemi, L., & Hemminki, A. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100219n · Cited by 123
Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy
Messmer, M. N., Netherby, C. S., Banik, D., & Abrams, S. I. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1639-3 · Cited by 122
Cetuximab-mediated Tumor Regression Depends on Innate and Adaptive Immune Responses
Yang, X., Zhang, X., Mortenson, E. D., Radkevich-Brown, O., Wang, Y., & Fu, Y. (2012) · Molecular Therapy · doi:10.1038/mt.2012.184 · Cited by 120
Self-citationLo, J. C., Chin, R., Lee, Y., Kang, H.-S., Wang, Y., Weinstock, J. V., Banks, T. A., Ware, C. F., Franzoso, G., & Fu, Y. (2003) · Journal of Clinical Investigation · doi:10.1172/jci19188 · Cited by 112
Self-citationTargeting the Primary Tumor to Generate CTL for the Effective Eradication of Spontaneous Metastases
Yü, P., Lee, Y., Wang, Y., Liu, X., Auh, S. L., Gajewski, T. F., Schreiber, H. W., You, Z., Kaynor, C., Wang, X., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.3.1960 · Cited by 79
Self-citationTähtinen, S., Grönberg-Vähä-Koskela, S. A. M., Lumén, D., Merisalo-Soikkeli, M., Siurala, M., Airaksinen, A. J., Vähä-Koskela, M. J. V., & Hemminki, A. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0220-t · Cited by 72
LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response
Zou, W., Zheng, H., He, T., Chang, J., Fu, Y., & Fan, W. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-4216 · Cited by 51
Self-citationImmune checkpoint combinations from mouse to man
Ai, M., & Curran, M. A. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1650-8 · Cited by 46
Direct and indirect roles of the LTβR pathway in central tolerance induction
Zhu, M., Brown, N. K., & Fu, Y. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.06.005 · Cited by 17
Self-citation
Cited by
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641
Self-citationConserved pan-cancer microenvironment subtypes predict response to immunotherapy
Bagaev, A., Kotlov, N., Nomie, K., Svekolkin, V., Gafurov, A., Isaeva, O., Osokin, N., Kozlov, I., Frenkel, F., Gancharova, O., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.04.014 · Cited by 1,302
Natural killer cells and other innate lymphoid cells in cancer
Chiossone, L., Dumas, P.-Y., Vienne, M., & Vivier, E. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0061-z · Cited by 1,007
Dong, Z.-Y., Zhong, W.-Z., Zhang, X.-C., Su, J., Xie, Z., Liu, S.-Y., Tu, H.-Y., Chen, H.-J., Sun, Y.-L., Zhou, Q., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2554 · Cited by 959
Metadata
- Authors
- Tang, H., Wang, Y., Chlewicki, L. K., Zhang, Y., Guo, J., Liang, W., Wang, J., Wang, X., & Fu, Y.-X.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2016-03
- Volume
- 29
- Issue
- 3
- Pages
- 285-296
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2294356527
- Cited by
- 472
- References
- 62
- FWCI
- 23.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.